Rolling review accelerates the NDA review process, reducing time-to-potential approval. Traders should watch for completion of the NDA submission in H2 2026 and any FDA communication on acceptance or priority review. The stock may re-rate on regulatory progress milestones.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 22 $118.84entry
- T+1 · 5mo ago −0.13%α +1.32% · $118.68
- T+5 · 5mo ago +24.71%α +26.78% · $148.21
- T+20 · 4mo ago +32.31%α +32.46% · $157.24
- T+60 · 2mo ago +27.25%α +25.50% · $151.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palvella Therapeutics announced that the FDA has granted rolling review for its NDA for QTORIN™ rapamycin to treat microcystic lymphatic malformations. The company remains on track to complete the NDA submission in the second half of 2026. This regulatory milestone accelerates the review timeline for a potential first-approved therapy in an indication with no current FDA-approved treatments, a significant catalyst for this clinical-stage biotech.
Key Facts
- FDA granted rolling review for QTORIN™ rapamycin NDA for microcystic lymphatic malformations.
- Palvella remains on track to complete NDA submission in the second half of 2026.
- QTORIN™ rapamycin has Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA.
- No FDA-approved therapies currently exist for the estimated 30,000+ U.S. patients with microcystic LMs.
- Positive Phase 3 SELVA results support the NDA submission.
Financial Impact
First-to-market potential in a rare disease with 30,000+ U.S. patients; no revenue or deal value disclosed.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) after review, including on safety/efficacy or CMC grounds.
- Commercial adoption depends on pricing, reimbursement, and competition from off-label systemic mTOR inhibitors.
- Company is clinical-stage with no approved products and may require additional capital to fund commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3315197 |
Track record
36 reports on PVLA
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers